Inhibiting transcription in cancers with aberrant KRAS expression has proven to be detrimental to tumor cells, revealing their dependency on KRAS independent of its mutational status and provides a wide scope for therapeutic intervention [12,13,14,15]. The gene discussed is KRAS; the disease is neoplasm.